Laurie Bauer
Cleveland Clinic
13 Papers
273 Citations
Laurie Bauer is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 9, co-authored 11 publications.
Chat about Author
Papers
•Journal Article
Clinical Results and Characterization of Tumor-infiltrating Lymphocytes with or without Recombinant Interleukin 2 in Human Metastatic Renal Cell Carcinoma
Ronald M. Bukowski,William Sharfman,Siva Murthy,Patricia Rayman,Raymond R. Tubbs,Jeannine Alexander,G. T. Budd,J. Sergi,Laurie Bauer,V. Gibson,Jill Stanley,James M. Boyett,Edson Pontes,James H. Finke +13 more
TL;DR: Results demonstrate that in vitro expansion of TILs is possible, but further studies are needed to define the biology of Tils in renal cancer and to isolate and expand tumor-specific T-cells.
107
Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis
Lisa R. Rogers,Paul M. Duchesneau,C. Nunez,A. J. Fishleder,James K. Weick,Laurie Bauer,James M. Boyett +6 more
TL;DR: Cisternal CSF cytologie examination should be considered in patients suspected of having leptomeningeal metastasis if lumbar CSF is nondiagnostic.
75
•Journal Article
Induction of cytokine messenger RNA and secretion in alveolar macrophages and blood monocytes from patients with lung cancer receiving granulocyte-macrophage colony-stimulating factor therapy.
Mary Jane Thomassen,Muzaffar Ahmad,Barbara P. Barna,J. M. Antal,Herbert P. Wiedemann,David P. Meeker,John S. Klein,Laurie Bauer,V. Gibson,Steven Andresen,Ronald M. Bukowski +10 more
TL;DR: It is indicated that GM-CSF exerts striking time-dependent modulatory effects on gene expression and functional activities of monocytes and alveolar macrophages in vivo, although the responses of the two cell types differ with respect to cytokine secretion.
49
•Journal Article
Phase I Trial of Dipyridamole with 5-Fluorouracil and Folinic Acid
George Thomas Budd,A. Jayaraj,David C. Grabowski,David J. Adelstein,Laurie Bauer,James M. Boyett,Ronald M. Bukowski,Sudish C. Murthy,James K. Weick +8 more
TL;DR: Phase II trials of the combination of dipyridamole, 5-fluorouracil (5-FU), and folinic acid in patients with advanced refractory malignancy are justified, based upon in vitro evidence that dipyridsamole can modulate the cytotoxicity of 5-FU.
33
Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers
O. Ortmann,Jens-Uwe Blohmer,Nora Tabea Sibert,S. Brucker,Achim Wöckel,Anton Scharl,Souleymane Dieng,Julia Ferencz,Elisabeth C. Inwald,Simone Wesselmann,Christopher E. Kowalski,E. K. Denisjuk,Roland Csorba,Daniela Rezek,Susanne Peschel,Dominik Denschlag,Friedemann Schad,D. Dieterle,Benno Lex,Luisa Rieger,Felix Flock,A. Cramer,H. J. Strittmatter,J. Bettscheider,Cecilia Lindnér,Andrea Stefek,Wladimir Pauker,Arnd Hönig,Michael G. Schrauder,D.Seeger,Anke Kleine-Tebbe,A. Bleimehl,Ursula Groh,Gerhard Gebauer,H.-W. Vollert,A. Zorr,W. Friedmann,P Krabisch,S. Fritz,A. Schwämmle,W. Lucke,Sabine Schmatloch,W. Heyl,Petra Deuschle,Michael C. Arfsten,P. Scheler,A. Ruf-Dördelmann,Barbara Brückner,Laurie Bauer,Martin Koch,Jaume Monner,A. Nixdorf,A. Merte,Frank Beldermann,Wolfgang Janni,Riccardo Felberbaum,R.L. De Wilde,P. Bolkenius,Antje Lebrecht,Olaf Ortmann,E. F. Solomayer,Steffi Hartmann,Andreas D. Hartkopf +62 more
TL;DR: In this article , the authors analyzed data from 94,638 patients treated in 55 breast cancer centers to describe the current clinical practice of and outcomes after NACT under routine conditions.